The HPS6 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the HPS6 gene in the human HT29 colorectal adenocarcinoma cell line. This polyclonal pool comprises a heterogeneous mixture of edited cells, enabling robust functional studies without the clonal bias inherent in single-cell-derived lines. The targeted disruption of HPS6 provides a loss-of-function model suitable for investigating intracellular trafficking and organelle biogenesis.
HT29 cells are a widely utilized human colorectal adenocarcinoma cell line with an epithelial phenotype, extensively employed in studies of intestinal epithelial biology, colorectal carcinogenesis, and drug response. Originating from a primary tumor, HT29 cells exhibit features of differentiated enterocytes under appropriate culture conditions, making them a versatile platform for exploring cancer-specific mechanisms and epithelial cell dynamics. When combined with HPS6 disruption, this background allows dissection of lysosome-related organelle function in the context of colorectal cancer.
HPS6 encodes a subunit of the biogenesis of lysosome-related organelles complex-2 (BLOC-2), which interacts with HPS3 and HPS5 to facilitate cargo sorting from early endosomes to lysosome-related organelles. BLOC-2 coordinates with the AP-3 adaptor complex and clathrin, downstream of transcriptional regulators such as MITF and TFEB, to mediate trafficking of transmembrane proteins including LAMP1, LAMP2, and tyrosinase. This trafficking pathway involves Rab GTPases and sorting nexin (SNX) proteins, with HPS6 disruption impairing the delivery of cargos to melanosomes, platelet dense granules, and lysosomes. Knockout cells thus exhibit defective organelle biogenesis and altered protein localization, mirroring Hermansky-Pudlak syndrome type 6 phenotypes.
In the HT29 colorectal cancer background, HPS6 knockout offers a unique tool to investigate how lysosome-related trafficking defects influence tumor cell behavior. Aberrant lysosomal function is increasingly recognized in cancer progression and drug resistance, and the HT29 HPS6 knockout polyclonal cells allow researchers to probe these connections. Altered LAMP1 surface expression, measurable by flow cytometry, correlates with changes in invasive potential or drug sensitivity. This model bridges basic intracellular trafficking studies and translational cancer research, facilitating the identification of vulnerabilities linked to organelle biogenesis defects.
The HPS6 Knockout HT29 Polyclonal Cells are suited for a broad range of biomedical assays, including Western blotting and RT-qPCR for confirmation of gene disruption, immunofluorescence microscopy to monitor lysosomal marker redistribution, and co-immunoprecipitation to assess BLOC-2 complex integrity. Functional studies such as migration and invasion assays can evaluate the impact of HPS6 loss on metastatic traits, while drug sensitivity profiling can uncover roles in therapeutic resistance. Additionally, flow cytometry for LAMP-1 provides a quantitative readout of lysosomal trafficking defects. These cells are an essential resource for researchers studying Hermansky-Pudlak syndrome, melanosome biogenesis, and the intersection of lysosome dysfunction with cancer. For further information, contact Ascent Research.
